skip to main content


Pure at heart

Haermonics is a clinical stage medtech company that prevents blood-related complications post open-heart surgery. Their pioneering product – the Haermonics PureTM – is a highly effective flushing therapy that demonstratively prevents excessive blood-loss and the need for costly re-operations following open-heart surgery.

The Mibiton Solo funds is used to finance the production of several investigational devices used in (multicenter) clinical validation studies.

Wouter Markus, CEO

"The swift and crystal clear decision process and understanding of our market and our proposition makes Mibiton a very valuable financing partner."